Patent · US Expired

Plasmodium falciparum vaccine comprising a recombinant histidine-rich protein-HRP-II

US5393523A · kind A · utility

1Cited by

2References

2Claims

0Family size

Assignee

Behringwerke Aktiengesellschaft · DE

Inventors

Bernard Knapp · Bad Neuenahr-Ahrweiler, DE
Erika Hundt · Marburg, DE
Burkhard Enders · Marburg, DE
Hans Kupper · Marburg, DE

Key dates

Filing date	Aug 20, 1993
Grant date	Feb 28, 1995
Priority date	—
Expiry date	Aug 20, 2013

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY10S530/855
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Recombinant histidine-rich protein of Plasmodium falciparum, its preparation and use. It was possible, by screening two different Plasmodium falciparum cDNA gene banks with an antiserum against a 41 kD protein and by cross-hybridization with the insert DNA of a clone obtained therewith, to isolate a gene which codes for a Histidine-Alanine-rich protein (HRP-II). This protein protects aotus monkeys from infection with P. falciparum and is thus a suitable constituent of a malaria vaccine.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.